Novel Therapies in Relapsed/Refractory Mantle Cell Lymphoma
Released On
August 12, 2024
Expires On
November 30, 2024
Media Type
Internet
Completion Time
50 minutes
Specialty
Hematology-Oncology
Topic(s)
Pharmacology, Oncology
This activity is provided by Association of Cancer Care Centers.
This activity is supported in part by funding from Lilly.
All healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of physicians, advanced practice providers, pharmacists, nurses, and medical professionals caring for patient with mantle cell lymphoma.
Program Overview
This video series aims to provide an overview of the latest treatments available for patients with relapsed or refractory mantle cell lymphoma. The series covers recent trial results, potential new therapies, and an analysis of considerations to bear in mind when deciding on treatment options. The series will also include a case study presentation and discussion between panelists. The series will cover:
- Updates on new therapies
- BTK inhibitors
- Case studies
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Understand the evolving treatment landscape for relapsed/refractory mantle cell lymphoma
- Discuss the optimal sequencing of therapies for R/R MCL
- Develop strategies to manage adverse events with novel therapies for R/R MCL
Faculty
John Burke, MD
Oncologist/Hematologist, Rocky Mountain Cancer Centers
Associate Chair, Hematology Research Program, US Oncology
Dr. Burke earned his undergraduate degree from Harvard University, where he graduated magna cum laude with an A.B. in History and Science in 1992. Dr. Burke went on to earn his medical degree from the Baylor College of Medicine in Houston in 1997 where he graduated with high honors. He completed a residency in Internal Medicine at the University of California at San Francisco and a fellowship in Medical Oncology and Hematology at the Memorial Sloan-Kettering Cancer Center in New York City. Dr. Burke joined Rocky Mountain Cancer Centers in 2003. He specializes in blood cancers, with an emphasis on lymphoid disorders, including lymphomas, chronic lymphocytic leukemia (CLL), and multiple myeloma. Dr. Burke is considered a national and international expert in blood cancers, lecturing primarily on lymphoid malignancies. He is very active in clinical research, helping to develop new therapies for lymphoid malignancies, and has published numerous articles in peer-reviewed medical journals, including the New England Journal of Medicine, Blood, and the Journal of Clinical Oncology. He currently serves as Editor-in-Chief for Targeted Therapies in Oncology and as an Associate Editor for JCO Oncology Practice. He is active in hematology and oncology professional societies, having recently served a term on the Ethics Committee of the American Society of Clinical Oncology (ASCO) and currently serving a term on the Committee on Practice of the American Society of Hematology (ASH). He serves as chair of the US Oncology Pathways Task Force.
Jeff Sharman, MD
Director of Research, Willamette Valley Cancer Institute
Medical Director of Hematology Research, US Oncology
Dr. Jeff Sharman is a community practice hematologist-oncologist at the Willamette Valley Cancer Institute in Eugene, Oregon. He has served as the medical director of Hematology Research for US Oncology network and now helps lead the Sarah Cannon Hematology program. He attended Massachusetts General Hospital for residency and Stanford University for fellowship where he helped develop the science for B-cell receptor signal inhibitors. He has helped develop multiple BTK inhibitors, PI3K inhibitors, polatuzumab, venetoclax, obinutuzumab among others.
Kirollos Hanna, PharmD, BCPS, PCOP, FACCC
Director of Pharmacy, Minnesota Oncology
Asst. Prof. of Pharmacy, Mayo Clinic
Dr. Hanna is board certified by the Board of Pharmacy Specialties in Oncology Pharmacy and Pharmacotherapy. He received his doctorate of pharmacy from Florida A&M University, completed his general residency at St. Thomas Hospital, Nashville, TN and his oncology residency at St. Luke's Mountain States Tumor Institute, Boise, ID.
He is currently the Director of Pharmacy at Minnesota Oncology and an Assistant Professor of Pharmacy at the Mayo Clinic College of Medicine. Dr. Hanna serves as an Associate Editor for the Journal of the Advanced Practitioner in Oncology (JADPRO).
Dr. Hanna’s research interests are focused on B-cell malignancies and genitourinary cancers. He has published over a dozen peer-reviewed manuscripts in various journals including Pharmacotherapy, AJHP, Drugs, JOPP, AJMC and JHOP.
Dr. Hanna is a recognized Fellow of the Association of Community Cancer Centers (ACCC) and a Board member of the National Community Oncology Dispensing Association (NCODA). He is also an active member of the Hematology/Oncology Pharmacy Association, the American College of Clinical Pharmacy, and the Advanced Practitioner Society For Hematology and Oncology.
Instructions for Participation and Credit
There are no fees for participating and receiving pariticpation credit for this enduring activity. To receive the participation credit participants must:
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
ACCC requires that faculty participating in any credit activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For content questions please contact: [email protected]